A Trial of MitoQ for the Treatment of People With Parkinson's Disease
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
In Parkinson's Disease, the mitochondrial membranes in cells that produce dopamine become
damaged by oxidants, leading to the death of these cells and progressive tremor, slowness of
movement and the loss of neurons in the substantia nigra (a part of the brain that is
involved in movement). Mitoquinone is targeted to reach the membrane of mitochondria and
provide protection from damaging oxidants. There are no treatments currently available to
slow the progression of PD and this trial will help advance the development of this unique
disease modifying drug.
This trial will enroll 120 participants with untreated early onset of PD. Participants will
be randomized to receive 1 of 3 treatments: 40 mg of MitoQ tablets, 80 mg of MitoQ tablets or
placebo. The researchers, participants and sponsor will all be blinded to the treatment
allocation. Participants will be assessed after 1, 2, 3, 6, 9, 12 months of treatment and
again 28 days after their last dose. The effectiveness of the trial drug will be measured via
the Unified Parkinson's Disease Rating Scale (UPDRS). The safety of the trial drug will be
monitored via regular participant examinations, blood tests, ECG and collecting information
on adverse events.